Lymphocyte Depleted Hodgkin Lymphoma, Intrapelvic Lymph Nodes (C81.36)

Name of the Condition

• Common Name: Lymphocyte Depleted Hodgkin Lymphoma, Intrapelvic Lymph Nodes
• Medical Terms: LD Hodgkin Lymphoma, Lymphocyte-Depleted Hodgkin Disease (intrapelvic lymph nodes)

Summary

Lymphocyte depleted Hodgkin lymphoma (LD Hodgkin lymphoma) is a rare and aggressive subtype of Hodgkin lymphoma. It is characterized by a scarcity of lymphocytes and a predominance of Reed-Sternberg cells in affected lymph nodes or tissues. This subtype often presents at an advanced stage and may involve extranodal sites, such as the liver or bone marrow. LD Hodgkin lymphoma is associated with a poorer prognosis compared to other Hodgkin lymphoma subtypes, though treatment advances have improved outcomes.

Causes

The exact cause of lymphocyte depleted Hodgkin lymphoma is not fully understood. It is thought to result from a combination of genetic mutations and environmental factors. Unlike other Hodgkin lymphoma subtypes, Epstein-Barr virus (EBV) is frequently associated with LD Hodgkin lymphoma, suggesting a potential viral role in its development. Genetic abnormalities and immune system dysregulation may also contribute.

Risk Factors

• Age: Most commonly diagnosed in adults, particularly those over 50.
• Immune Status: Weakened immunity (e.g., from HIV/AIDS or immunosuppressive therapy) increases risk.
• Epstein-Barr Virus: Prior infection is strongly associated with this subtype.
• Geographic Region: Higher incidence in certain regions, possibly due to environmental or genetic factors.

Symptoms

Symptoms may include painless swelling of intrapelvic lymph nodes, fever, night sweats, unexplained weight loss, fatigue, and pruritus. Advanced disease can cause organ dysfunction or systemic symptoms.

Diagnosis

Diagnosis involves a biopsy of the affected intrapelvic lymph node to identify Reed-Sternberg cells and assess lymphocyte depletion. Imaging (e.g., CT, MRI) evaluates disease extent. Staging determines involvement of other sites.

Treatment Options

Treatment typically includes chemotherapy (e.g., ABVD or BEACOPP regimens) and may involve radiation therapy for localized disease. Stem cell transplantation is considered for relapsed or refractory cases. Immunotherapy (e.g., checkpoint inhibitors) is under investigation.

Prognosis and Follow-Up

Prognosis is poorer than other Hodgkin lymphoma subtypes due to advanced presentation. Regular follow-up with imaging and clinical assessments monitors for recurrence or complications. Long-term survivors may require surveillance for late effects.

Complications

Complications include treatment-related toxicities (e.g., cardiopulmonary, infertility), secondary malignancies, and disease progression. Intrapelvic involvement may cause organ compression or dysfunction.

Lifestyle & Prevention

No specific prevention exists. Maintaining a healthy immune system and avoiding known risk factors (e.g., smoking, excessive alcohol) may support overall health. Early symptom recognition aids timely diagnosis.

When to Seek Professional Help

Seek care for persistent lymph node swelling, unexplained weight loss, fever, or night sweats. Prompt evaluation is critical for early intervention and improved outcomes.

Tips for Medical Coders

Code C81.36 is specific to lymphocyte depleted Hodgkin lymphoma involving intrapelvic lymph nodes. Documentation must specify the site (intrapelvic) and confirm the histologic subtype (lymphocyte depleted) to support accurate coding. Ensure alignment with ICD-10-CM guidelines for site-specific lymphoma codes.